Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia

Blood

Volumn 108, Issue 13, 2006, Pages 3997-4002

  Hijiya, Nobuko ^a   Panetta, John C ^b   Zhou, Yinmei ^b   Kyzer, Emily P ^b   Howard, Scott C ^b   Jeha, Sima ^b   Razzouk, Bassem I ^b   Ribeiro, Raul C ^b   Rubnitz, Jeffrey E ^b   Hudson, Melissa M ^b   Sandlund, John T ^b   Pui, Ching Hon ^b   Relling, Mary V ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; TENIPOSIDE; TIOGUANINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGY; ARTICLE; BLOOD CLOTTING; BLOOD TOXICITY; BODY MASS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CONSTITUTIONAL SYMPTOM; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG MEGADOSE; ENDOCRINE DISEASE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LIVER TOXICITY; LOW DRUG DOSE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEPHROTOXICITY; NEUROTOXICITY; OBESITY; PAIN; PRIORITY JOURNAL; SIDE EFFECT; SKIN TOXICITY; SYMPTOM; SYNDROME; TREATMENT OUTCOME; UNDERWEIGHT;

EID: 33845504278     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-05-024414     Document Type: Article

References (38)

1. Dietz WH, Robinson TN. Clinical practice: overweight children and adolescents. N Engl J Med. 2005;352:2100-2109.
2. Bastarrachea J, Hortobagyi GN, Smith TL, Kau SW, Buzdar AU. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med. 1994;120:18-25.
3. Hafron J, Mitra N, Dalbagni G, et al. Does body mass index affect survival of patients undergoing radical or partial cystectomy for bladder cancer? J Urol. 2005;173:1513-1517.
4. Georgiadis MS, Steinberg SM, Hankins LA, Ihde DC, Johnson BE. Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst. 1995;87:361-366.
5. Berclaz G, Li S, Price KN, et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol. 2004;15:875-884.
6. Meyerhardt JA, Catalano PJ, Haller DG, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003;98:484-495.
7. Meloni G, Proia A, Capria S, et al. Obesity and autologous stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplant. 2001;28:365-367.
8. Lange BJ, Gerbing RB, Feusner J, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA. 2005;293:203-211.
9. Butturini A, Drey F, Gaynon P, et al. Obesity and body weight independently predict relapse and survival in preadolescents and teenagers with acute lymphoblastic leukemia (ALL): retrospective analysis of five Children Cancer Group (CCG) studies [abstract]. Blood. 2004;104:284a. Abstract 992.
10. Gomez-Almaguer D, Ruiz-Arguelles GJ, Ponce-De-Leon S. Nutritional status and socio-economic conditions as prognostic factors in the outcome of therapy in childhood acute lymphoblastic leukemia. Int J Cancer Suppl. 1998;11:52-55.
11. Lobato-Mendizabal E, Ruiz-Arguelles GJ, Marin-Lopez A. Leukaemia and nutrition, I: malnutrition is an adverse prognostic factor in the outcome of treatment of patients with standard-risk acute lymphoblastic leukaemia. Leuk Res. 1989;13:899-906.
12. Viana MB, Murao M, Ramos G, et al. Malnutrition as a prognostic factor in lymphoblastic leukaemia: a multivariate analysis. Arch Dis Child. 1994;71:304-310.
13. Weir J, Reilly JJ, McColl JH, Gibson BE. No evidence for an effect of nutritional status at diagnosis on prognosis in children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 1998;20:534-538.
14. Colleoni M, Li S, Gelber RD, et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet. 2005;366:1108-1110.
15. Rogers PC, Meacham LR, Oeffinger KC, Henry DW, Lange BJ. Obesity in pediatric oncology. Pediatr Blood Cancer. 2005;45:881-891.
16. Berg SL, Bomgaars L, Twist C, et al. Impact of body composition on pharmacokinetics of doxorubicin in pediatric patients: a Glaser Pediatric Research Network study [abstract]. J Clin Oncol. 2005;23:804s. Abstract 8519.
17. Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998;338:499-505.
18. Pui CH, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998;92:411-415.
19. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004;104:2690-2696.
20. Kishi S, Griener J, Cheng C, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol. 2003;21:3084-3091.
21. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91:2001-2008.
22. Ogden CL, Kuczmarski RJ, Flegal KM, et al. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics. 2002;109:45-60.
23. Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA. 2004;291:2847-2850.
24. Wall AM, Gajjar A, Link A, et al. Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia. 2000;14:221-225.
25. Panetta JC, Wilkinson M, Pui CH, Relling MV. Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia. J Pharmacokinet Pharmacodyn. 2002;29:171-188.
26. Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood. 1999;93:2817-2823.
27. Steimer JL, Mallet A, Golmard JL, Boisvieux JF. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev. 1984;15:265-292.
28. Menard S. Applied Logistic Regression Analysis. Thousand Oaks, CA: Sage Publications; 2002.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1968;53:457-481.
30. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
31. Cox DR. Regression models and life tables. J R Stat Soc Ser B. 1972;20:187-220.
32. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980.
33. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
34. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
35. Murry DJ, Riva L, Poplack DG. Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl. 1998;11:48-51.
36. Powis G, Reece P, Ahmann DL, Ingle JN. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol. 1987;20:219-222.
37. Dunn TE, Ludwig EA, Slaughter RL, Camara DS, Jusko WJ. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther. 1991;49:536-549.
38. Zuccaro P, Guandalini S, Pacifici R, et al. Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Ther Drug Monit. 1991;13:37-41.